Drug Reimportation Rejected Again

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WASHINGTON-A second Secretary of Health and Human Services (HHS), Tommy G. Thompson, has refused to allow the reimporting of US-made prescription drugs back into the country. Former HHS Secretary Donna E. Shalala made the same determination last December.

WASHINGTON—A second Secretary of Health and Human Services (HHS), Tommy G. Thompson, has refused to allow the reimporting of US-made prescription drugs back into the country. Former HHS Secretary Donna E. Shalala made the same determination last December.

Under the Medicine Equity and Drug Safety (MEDS) Act, signed into law last year, US-made prescription drugs exported to certain foreign nations could be reimported for sale to US consumers. US medications sell for less abroad, and the law’s intent was that reimported drugs would be sold at below normal prices.

MEDS included a provision that required the HHS Secretary to determine that, if reimportation occurred, the United States could maintain adequate safety and prices could be expected to be reduced. Mr. Thompson found that would not be the case.

"Opening our borders as required under this program would increase the likelihood that the shelves of pharmacies across the nation would include counterfeit drugs, cheap foreign copies of FDA-approved drugs, expired drugs, contaminated drugs, and drugs stored under inappropriate and unsafe conditions," the Secretary said in a letter to Sen. James Jeffords (I-Vt).

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content